Exosome Diagnostic and Therapeutic Market to Reach $2.9 Bn, Globally, by 2030 at 29.4% CAGR

According to the report, the global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030.

Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/1723

Determinants of growth-

Increase in use of multifunctional property of exosome therapy for chronic heart failure, Alzheimer's disease, Parkinson's disease, and cancer drive the growth of the global exosome diagnostic and therapeutic market. On the other hand, rise in demand for drug therapies and surge in R&D activities in the pharmaceutical and biopharmaceutical fields supplement the market growth even more. Moreover, surge in potential application of exosomes in cancer diagnosis and development of translational precision medicines are expected to create lucrative opportunities in the industry.

The diagnostic segment to dominate by 2030-

Based on application, the diagnostic segment accounted for more than two-thirds of the global exosome diagnostic and therapeutic market share in 2020, and is anticipated to rule the roost by 2030. The same segment would also cite the fastest CAGR of 29.5% throughout the forecast period, due to rise in incidence of chronic disease and surge in demand for early diagnosis.

Ask to Our Industry Expert:

https://www.alliedmarketresearch.com/purchase-enquiry/1723

The instrument segment to maintain the lion's share-

Based on product, the instrument segment held nearly three-fifths of the global exosome diagnostic and therapeutic market revenue in 2020, and is expected to lead the trail by 2030. This is owing to increase in need for molecular diagnosis and surge in R&D activities for the purpose of diagnosis. The software segment, on the other hand, would manifest the fastest CAGR of 30.2% from 2020 to 2030. This is attributed to advancements in R&D activities in the healthcare sector and increase in number of key manufacturers across the world.

North America garnered the major share in 2020-

Based on region, North America held the major share in 2020, generating nearly two-fifths of the global exosome diagnostic and therapeutic market, due to rise in product launches for exosome therapeutics, surge in the presence of key players, and development of R&D activities in the pharmaceutical and biopharmaceutical sector across the province. Asia-Pacific, however, would grow at the fastest CAGR of 30.3% by 2030. Increase in the prevalence of chronic and infectious disorders, growth in health care expenditures, and surge in demand for molecular diagnosis drive the market growth in the region.

Key players in the industry-

Exosome Diagnostics Inc.
NanoSomix Inc.
Thermo Fisher Scientific Inc.
Malvern Instruments Ltd.
System Biosciences Inc.
NX Pharmagen
Aethlon Medical, Inc.
Sistemic Inc.

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of 'Market Research Reports' and 'Business Intelligence Solutions'. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

This release was published on openPR.